Anpac Bio Technology, USA
The best way to beat cancer is to catch it early!
The best way to beat cancer is to catch it early!
Anpac Bio Technology, USA
Anpac Bio Technology is a leading biotechnology company focused on early cancer and disease screening, detection, and diagnostic technology. The company's proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy technology has shown promising results in identifying cancer pre-Stage One, with a sensitivity and specificity rate range of 70%-95% for over 26 different types of cancer.
The company, founded in 2010, has garnered significant attention for its groundbreaking approach to cancer detection, positioning itself as a key player in the biotechnology and healthcare industries. Anpac Bio's commitment to excellence, creativity, and social responsibility highlights its potential for growth and impact in the global health landscape.
With its most recent Post-IPO Equity investment at 06 March 2023, Anpac Bio is poised to further advance its innovative technologies and expand its reach in the healthcare sector, presenting an intriguing opportunity for potential investors seeking to support cutting-edge advancements in early disease detection.
For more information on Anpac Bio-Medical Science Company, please visit www.AnpacBio.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | Unknown | - | 06 Mar 2023 | |
| Post-IPO Equity | Unknown | - | 26 Sep 2022 | |
| Post-IPO Equity | Unknown | - | 11 Apr 2022 | |
| Post-IPO Equity | Unknown | - | 09 Nov 2021 | |
| Grant | Unknown | - | 07 Oct 2020 |
No recent news or press coverage available for Anpac Bio Technology, USA.
We care about your data, and we'd love to use cookies make your experience better.
